Track topics on Twitter Track topics that are important to you
Gemtuzumab ozogamicin, a CD33-targeted therapy for acute myeloid leukaemia (AML), significantly improves outcomes compared with standard chemotherapy in patients with a specific CD33 splicing polymorphism genotype, according to a recent study.
Original Article: [News] Potential biomarker for acute myeloid leukaemia therapyNEXT ARTICLE
Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells. Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...